Managers / Q1 2020 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $257M in U.S.-listed holdings across 14 positions for Q1 2020.
Its largest position, QURE, represents 9.3% of the portfolio.
Compared with Q4 2019, the fund opened 3 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 56.8% · $146M
- ETP · 30.2% · $77M
- Other · 8.8% · $23M
- ADR · 4.3% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ANABANAPTYSBIO INC | NEW | +1.44M | 1.44M | +$20M | $20M |
| NGM BIOPHARMACEUTICALS INC | NEW | +1.05M | 1.05M | +$13M | $13M |
| ARWRARROWHEAD PHARMACEUTICALS IN | NEW | +436.5K | 436.5K | +$13M | $13M |
| MORPHOSYS AG | ADDED | +89.8K | 95.9K | +$2M | $2M |
| DICERNA PHARMACEUTICALS INC | ADDED | +622.9K | 1.24M | +$9M | $23M |
| FATEFATE THERAPEUTICS INC | SOLD OUT | −72.3K | 0 | −$1M | $0 |
| SPROSPERO THERAPEUTICS INC | ADDED | +663.8K | 1.82M | +$4M | $15M |
| GALAPAGOS NV | TRIMMED | −27.7K | 44.2K | −$6M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | QUREUNIQURE NVhistory → | SHS | 9.28% | $24M | 502.0K |
| 2 | DICERNA PHARMACEUTICALS INC | COM | 8.86% | $23M | 1.24M |
| 3 | ANABANAPTYSBIO INChistory → | COM | 7.92% | $20M | 1.44M |
| 4 | XENEXENON PHARMACEUTICALS INChistory → | COM | 6.63% | $17M | 1.50M |
| 5 | SPROSPERO THERAPEUTICS INChistory → | COM | 5.73% | $15M | 1.82M |
| 6 | PROQR THRAPEUTICS N V | SHS EURO | 5.14% | $13M | 2.40M |
| 7 | NGM BIOPHARMACEUTICALS INC | COM | 5.03% | $13M | 1.05M |
| 8 | PIERIS PHARMACEUTICALS INC | COM | 4.95% | $13M | 5.58M |
| 9 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 4.89% | $13M | 436.5K |
| 10 | MERUS N V | COM | 3.63% | $9M | 770.2K |
| 11 | RGNXREGENXBIO INChistory → | COM | 3.45% | $9M | 273.2K |
| 12 | GALAPAGOS NV | SPON ADR | 3.38% | $9M | 44.2K |
| 13 | MORPHOSYS AG | SPONSORED ADS | 0.92% | $2M | 95.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.